Clinical Trial Update: PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PHESGO maintenance after short induction with trastuzumab deruxtecan in HER2-positive unresectable locally recurrent or metastatic brea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PHESGO (PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF)
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: MedSIR | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: RECRUITING